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70% in 2009. In unadjusted analysis, the cumulative rates of 
all-cause mortality, EC-specific mortality, and cardiac 
mortality were significantly lower in the IMRT vs 3DCRT group 
(all: 52.4% vs 74.5%, p<0.0001; EC: 40.3% vs. 55.6%, 
p<0.0001; and cardiac: 1.6% vs. 5.3%, p=0.0043). However, 
no difference was seen in deaths from pulmonary (0.96% vs. 
1.55%, p=0.419) or other causes (9.6% vs. 12.1%, p=0.204). On 
propensity score-adjusted MVA, IMRT was not associated with 
EC-specific mortality (HR 0.87, 95%CI 0.69-1.06), pulmonary 
(HR 1.04, 95%CI 0.29-3.79) or other cause mortality (HR 0.81, 
95%CI 0.54-1.22) but was significantly associated with lower 
all-cause mortality (HR 0.83, 95%CI 0.70-0.98) and lower 
cardiac mortality (HR 0.35, 95%CI 0.14-0.88). Similar 
associations were seen adjusting for physician experience and 
sensitivity analysis removing hybrid radiation claims.  
Conclusions: In this population-based analysis, IMRT use was 
significantly associated with lower all-cause mortality and 
cardiac mortality in patients with esophageal cancer. 
   
OC-0125   
Cyberknife-based reirradiation for head and neck cancers: 
dosimetric analysis and clinical impact on carotid vessels 
S. Goyal1, T. Kataria1, T. Basu1, D. Gupta1, A. Abhishek1, S.S. 
Bisht1, K.P. Karrthick1 
1Medanta - The Medicity, Division of Radiation Oncology, 
Gurgaon, India  
 
Purpose/Objective: Carotid blowout is an uncommon but 
serious complication of salvage reirradiation (Re-RT) for head 
and neck cancers (HNC). We evaluated carotid artery doses in 
high dose regions during CyberKnife-based fractionated 
stereotactic reirradiation (CK-FSRT) of HNC, and correlated 
them to complication risk. 
Materials and Methods: Patients who received CK-FSRT from 
October 2012 to April 2014 were included. Entire course of 
internal or common carotid arteries ipsilateral to the high 
dose region either within or adjacent to the target volume 
was contoured, and doses to these vessels evaluated (Dmax, 
Dmean, D0.2 cc, D0.5cc, D1cc, V25, V30). The clinical course 
including responses and complications were prospectively 
recorded. 
Results: Twenty-two patients received CK-FSRT during this 
period; of these, 13 (11 males, 2 females) with median age 
56 years (range 31-83 years) received reirradiation, either for 
second primary (2) or recurrence (11); dose being 20-37.5 Gy 
in 3-7 fractions (commonest schedule, 30 Gy in 5 fractions). 
The median interval between the two RT courses was 13 
months (range 3.8-47.7 months). All patients had earlier 
received a dose of 64-70 Gy to the Re-RT region. Median 
follow up post CK-FSRT was 9 months (range 2-19 months). 
During this period, one patient developed carotid bleed 7 
months post-Re-RT that was successfully salvaged with 
angioembolization. There were no treatment-related deaths. 
Dose-volumes were noted for 17 vessels in 13 patients where 
carotid Dmax exceeded 24 Gy for the Re-RT course. Median 
integral dose (volume in ml X dose in Gy) to the vessels was 
41.8 ml-Gy (range 22.4-71.6). Median Dmax (range), D0.2cc 
(range) and D1cc (range) were 33.5 Gy (24.1-44.1), 30.6 Gy 
(22.0-37.6), and 20.37 Gy (7.6-37.6), respectively. Median 
V25 and V30 were 1.08 cc (39.7%) and 0.7 cc (29.7%), 
respectively. Median BED3 maximum and for 0.2 cc volume of 
carotid were 100 Gy (55-146 Gy) and 92.3 Gy (39.9-137.3 Gy), 
respectively for the FSRT plan, and median composite BED3 
maximum was 225 Gy (189-252 Gy). Six patients (7 vessels) 
had at least 50% volume within PTV. The patient who 
developed bleeding was a 73-year lady who had earlier 
undergone surgeries for 2 primaries. The first and repeat 
irradiation interval was 47.7 months and the respective dose-
volume parameters for Re-RT (30 Gy in 5 fractions, 
prescribed to 74% isodose) were: Dmax 39.9 Gy, Dmean 36.2 
Gy, BED3 Dmax (FSRT) 146 Gy, composite BED3 Dmax 252 Gy, 
and V30 18.9cc (100%). 
Conclusions: During SBRT Re-RT, it is advisable to keep 
carotid Dmax BED3 (FSRT & composite) below 145 Gy & 220 
Gy, respectively, though several other factors such as 
diabetes, carotid encasement, number of FSRT fractions, 
inter-RT interval & mucosal involvement contribute to risk. 
Evaluation of a larger number of patients with longer follow 
up and more events would help estimate the relationship 
between carotid doses and observed toxicity, which would 
serve as a useful reference to define respective dose 
constraints for Re-RT.   
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The introduction of 3D image guided brachytherapy has been 
instrumental for reaching new knowledge about dose and 
effect in locally advanced cervix cancer treated with 
combined external beam radiotherapy and brachytherapy. 
Previous to the era of 3D image guided brachytherapy, dose 
assessment was mainly based on points for primary tumour 
(point A) and organs at risk (ICRU bladder and rectum points, 
and applicator related vagina points). ICRU rectum point dose 
has been a successful predictor for rectal bleeding - however, 
the point dose assesments associated with tumour, bladder 
and vagina has not been sufficiently specific to result in 
consistent evidence on dose and effect for local control and 
bladder/vaginal morbidity. During the last decade, the GEC 
ESTRO recommendations on contouring, dose reporting, 
applicator reconstruction and imaging for 3D MRI guided 
brachytherapy have spread throughout the world. This has 
significantly moved the field forward, and currently, a vast 
new experience is being built up on dose and effect with 
regard to both tumour control and morbidity. 
As one of the largest clinical initiatives in 3D image guided 
brachytherapy, the GEC ESTRO Gyn network initiated the 
prospective EMBRACE trial in 2008 (International Study of MRI 
guided Brachytherapy in Cervix Cancer) 
(www.embracestudy.dk). EMBRACE comprises 27 key 
international centers who deliver MRI guided brachytherapy 
in locally advanced cervical cancer according to the GEC 
ESTRO recommendations. The aim of the EMBRACE protocol is 
to benchmark MRI guided brachytherapy in a multicenter 
setting within the frame of a prospective observational study 
and to correlate image based DVH parameters for the clinical 
target volume and for organs at risk with outcome. More than 
1200 patients have been enrolled, and accrual will finalize in 
2015. Furthermore, the retrospective retroEMBRACE study 
has enrolled >700 patients treated with image guided 
brachytherapy from 12 international centers 
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(www.retroembrace.com). Data from the EMBRACE and 
retroEMBRACE studies show significant correlation between 
dose and outcome for both local control and morbidity 
(bladder, rectum, bowel, vagina).  
While there is currently not international consensus on dose 
planning aims and dose prescription in cervix cancer, the 
dose effect data from the EMBRACE and retroEMBRACE 
studies will change this situation. The upcoming evidence can 
be used to recommend certain dose planning aims and dose 
prescription levels. A new study (EMBRACE II) will for the first 
time implement a prospective dose prescription protocol for 
both target and organs at risk based on clinical outcome data 
from EMBRACE and retroEMBRACE. EMBRACE II will be 
initiated in 2015. 
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Image guided adaptive brachytherapy (IGABT) as part of 
combined radiochemotherapy for locally advanced cervical 
cancer is associated with improved rates of local control with 
simultaneous decrease in morbidity compared to use of 
standard brachytherapy plans in several institutional series.  
Besides tumor control and morbidity, health related quality 
of life (HR-QoL) including patient reported symptoms can 
provide additional important information to evaluate 
treatment efficacy. While clinician-assessed morbidity scales 
are objectively defined, patient reported symptoms provide a 
subjective evaluation without clinical interpretation. Several 
studies have pointed out that there can be considerable 
underreporting of morbidity when patient reported symptoms 
are taken into account, especially for low grade morbidity.  
Comparison of HR-QoL results with age matched normal 
population data can help to point out which symptoms or 
issues are most prevalent during further follow-up after 
treatment. In addition these results can provide patients with 
more detailed information on what to expect during follow-
up.  
Most HR-QoL studies in patients with cervical cancer report 
on a cross-sectional cohort, are not prospective, and have 
included patients with different treatments and 
gynaecological malignancies. Despite these limitations, in 
general radiochemotherapy for locally advanced cervical 
cancer has found to have a considerable impact on HR-QoL 
and patient reported symptoms. During treatment patients 
report more symptoms of fatigue, nausea, appetite loss, 
diarrhea, pain and insomnia, affecting global health status 
and emotional, social and role functioning,although part of 
these symptoms recover over time. Most studies with longer 
follow-up after treatment still find impairments in 
functioning compared to the general population. And some of 
the symptoms may persist years after treatment, like 
diarrhea, urinary frequency and leaking of urine. In addition, 
survivorship studies indicate that sexual symptoms are 
prevalent and sexual functioning is frequently impaired and a 
major source of distress. 
The EMBRACE study (www.embracestudy.dk) investigated the 
introduction of IGABT in a multicentre setting and included 
prospective HR-QoL assessment with EORTC quality of life 
questionnaires. This trial started in 2008 and has included 
over 1200 patients. In an interim EMBRACE report, a 
comparison between CTCAE morbidity and EORTC patient 
reported symptoms confirmed that there was considerable 
underestimation between both endpoints.  
Preliminary EMBRACE HR-QoL results of this study including a 
comparison with age matched norm population data will be 
presented.  
In conclusion, HR-QoL outcomes provide useful additional 
information besides tumor control and clinician-assessed 
morbidity. These outcomes provide useful information when 
counselling patients on what to expect regarding functioning 
and symptoms. Patient reported HR-QoL and symptom 
endpoints can play and important role in future research in 
order to to optimize the therapeutic window, to decrease 
most prevalent symptoms and to increase patient functioning 
and HR-QoL during follow-up.  
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Purpose/Objective: To identify prognostic factors for local 
control in patients treated for locally advanced cervical 
cancer with image guided adaptive brachytherapy, and 
analyse their potential impact on planning aims. 
Materials and Methods: Patients treated with curative intent 
by a combination of external beam radiotherapy and pulsed-
dose rate brachytherapy were selected. Local failure was 
defined as any relapse in the cervix, vagina, parametria, or 
uterus during follow-up. Prognostic factors were selected 
based on log rank tests and then analyzed with a Cox model. 
Dose/effect correlations were performed using the Probit 
model. 
Results: Two hundred and twenty-five patients treated from 
2006 to 2011 were included. According to the FIGO 
classification, 29% were stage IB, 58% stage II, 10% stage III, 
and 3% stage IVA; 95% received concomitant chemotherapy. 
Thirty patients were considered having incomplete response 
or local failure. Among the selected parameters, D90 for HR-
CTV, D90 for IR-CTV, the overall treatment time, the TRAK, 
and the HR-CTV volume appeared significantly correlated 
with local control in univariate analysis. In multivariate 
analysis, overall treatment time > 55 days and HR-CTV 
volume > 30 cm3 appeared independent.  
The Probit analysis showed significant correlations between 
the D90 for both CTVs, and the probability of achieving local 
control (p=0.008 and 0.024). The thresholds to reach to 
warrant a probability of 90% of local control were 85 Gy to 
